Drs Matulonis and Porter discuss the role of immunotherapy in gynecologic cancer management, focusing on clinical breakthroughs and future directions.
Rebecca L. Porter, MD, PhD
Advertisement
Rebecca Porter, MD, PhD, is a physician at Dana-Farber Cancer Institute and an assistant professor of medicine at Harvard Medical School.
Articles by Rebecca L. Porter, MD, PhD
Rebecca L. Porter, MD, PhD, discusses the evaluation of mirvetuximab soravtansine plus pembrolizumab in FRα-positive, pMMR/MSS endometrial cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
4
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
5